ANDA Litigation Settlements

Case Name Drug Patent No(s). Publicly Available Terms
AstraZeneca AB v. Mylan Pharms. Inc., 17-1778 (Fed. Cir.) Onglyza® (saxagliptin HCl tablets)
Kombiglyze XR™ (saxagliptin HCl / metformin HCl extended-release tablets)
RE44,186 The Federal Circuit granted a joint motion by the parties to voluntarily drop the appeal with each side bearing its own fees and costs.
The district court concluded that patent-in-suit claims were non-obviousness.

The articles on our Website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice.